Michael R. Dougherty Joins the Board of ViralClear Pharmaceuticals, a majority-owned subsidiary of BioSig Technologies, Inc.
May 28 2020 - 8:40AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”) today appointed Mr. Michael R. Dougherty to the Board of
Directors of its majority-owned subsidiary ViralClear
Pharmaceuticals, Inc.
Mr. Dougherty brings to ViralClear over 30 years of experience
in the pharmaceutical industry, most recently serving as Executive
Chairman of Celator Pharmaceuticals, Inc. (sold to Jazz
Pharmaceuticals). Prior to Celator, Mr. Dougherty served as Chief
Executive Officer and a member of the board of directors of Kalidex
Pharmaceuticals, Inc. Earlier in his career Mr. Dougherty
also served in a number of roles during his ten-year tenure at
Adolor Corporation, including President and Chief Executive
Officer, member of the board of directors, Chief Operating Officer,
and Chief Financial Officer. Prior to Adolor, Mr. Dougherty was
President and Chief Operating Officer of Genomics Collaborative,
Inc. and served in a variety of senior positions at Genaera
Corporation, including President and Chief Executive Officer and
member of the board of directors, and at Centocor, Inc. Mr.
Dougherty is currently serving on the board of directors at Idera
Pharmaceuticals, Inc, Marinus Pharmaceuticals, Inc. and Trevena,
Inc., and previously served on the boards of Foundation Medicine,
Inc., Celator Pharmaceuticals, Inc, Aviragen Therapeutics, Cempra,
Inc., and Viropharma Incorporated. Mr. Dougherty received a
bachelor’s degree in accounting from Villanova University.
“Michael’s broad executive, operational and governance
experience in biotech is highly beneficial to our team at this
critically important time. We look forward to Michael’s
contrubutions as we progress in our clinical plans,” commented
Jerome Zeldis, M.D., Ph.D, Executive Chair of ViralClear
Pharmaceuticals, Inc.
Mr. Dougherty joins the former Chief Medical Officer of Celgene
Jerome Zeldis, M.D., Ph.D, Nick Spring, CEO of ViralClear and a
former senior executive at Merck & Co., Anthony Zook, former
senior executive at Astra Zeneca, Plc and Dennis Purcell, the
founder of Aisling Capital on the Board of ViralClear.
“I am impressed with the accomplishments that this young company
achieved in such a short period of time, and, and I look forward to
working with the team and contributing my knowledge and expertise
to ViralClear,” commented Mr. Dougherty.
About merimepodibAnti-viral candidate
merimepodib (MMPD) targets RNA-dependant polymerases. The molecule
has shown activity against a broad spectrum of RNA viruses and has
demonstrated satisfactory safety data from over 300 patients
treated for hepatitis C. Recently, the Company published first
pre-clinical data generated under contract with Galveston National
Laboratory at The University of Texas Medical Branch. The Company
recently submitted two manuscripts titled“The IMPDH inhibitor
merimepodib provided in combination with the adenosine analogue
remdesivir reduces SARS-CoV-2 replication to undetectable levels in
vitro” and “The IMPDH inhibitor merimepodib suppresses SARS-COV-2
replications”. The manuscripts were authored by Natalya Bukreyeva,
Emily K. Mantlo, Rachel A. Sattler, Cheng Huang, John T. Manning,
Slobodan Paessler, DVM, Ph.D of the UTMB Galveston National
Laboratory and Jerome Zeldis, M.D., Ph.D of ViralClear. In-vitro
studies referenced in the manuscript demonstrated that merimepodib
decreased viral production by over 98%. About BioSig
Technologies BioSig Technologies is a medical technology
company commercializing a proprietary biomedical signal processing
platform designed to improve signal fidelity and uncover the full
range of ECG and intra-cardiac signals (www.biosig.com).
The Company’s first product, PURE EP(tm) System is a
computerized system intended for acquiring, digitizing, amplifying,
filtering, measuring and calculating, displaying, recording and
storing of electrocardiographic and intracardiac signals for
patients undergoing electrophysiology (EP) procedures in an EP
laboratory.
About ViralClearBioSig’s subsidiary ViralClear
Pharmaceuticals, Inc., is seeking to develop a novel pharmaceutical
to treat COVID-19. Merimepodib is intended to be an orally
administered, broad-spectrum anti-viral agent that has demonstrated
strong activity against COVID-19 in cell cultures in laboratory
testing. The product candidate has completed Phase I and three
Phase II trials in other indications.
Forward-looking Statements This press release
contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,”
“anticipates,” “projects,” “predicts,” “estimates,” “aims,”
“believes,” “hopes,” “potential” or similar words. Forward- looking
statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown
risks and uncertainties, many of which are beyond the Company’s
control, and cannot be predicted or quantified and consequently,
actual results may differ materially from those expressed or
implied by such forward-looking statements. Such risks and
uncertainties include, without limitation, risks and uncertainties
associated with (i) the geographic, social and economic impact of
COVID-19 on our ability to conduct our business and raise capital
in the future when needed, (ii) our inability to manufacture our
products and product candidates on a commercial scale on our own,
or in collaboration with third parties; (iii) difficulties in
obtaining financing on commercially reasonable terms; (iv) changes
in the size and nature of our competition; (v) loss of one or more
key executives or scientists; and (vi) difficulties in securing
regulatory approval to market our products and product candidates.
More detailed information about the Company and the risk factors
that may affect the realization of forward-looking statements is
set forth in the Company’s filings with the Securities and Exchange
Commission (SEC), including the Company’s Annual Report on Form
10-K and its Quarterly Reports on Form 10-Q. Investors and security
holders are urged to read these documents free of charge on the
SEC’s website at http://www.sec.gov. The Company assumes no
obligation to publicly update or revise its forward-looking
statements as a result of new information, future events or
otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
54 Wilton Road, 2nd floor
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Mar 2024 to Apr 2024
BioSig Technologies (NASDAQ:BSGM)
Historical Stock Chart
From Apr 2023 to Apr 2024